Advancing treatment strategies against MRSA: unveiling the potency of tubuloside A in targeting sortase A and mitigating pathogenicity
World Journal of Microbiology and Biotechnology · 2025
DOI: 10.1007/s11274-024-04185-7 ↗Kurz gefasst
Fachartikel in der Zeitschrift World Journal of Microbiology and Biotechnology, 2025. Verfasst von Yangming Xu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Medical College, Changchun University of Chinese Medicine, Changchun, China. Hauptthemen laut MEDLINE: Aminoacyltransferases, Methicillin-Resistant Staphylococcus aureus, Cysteine Endopeptidases, Bacterial Proteins. Die Arbeit nennt 33 Literaturangaben. Gefördert von: Education Department of Jilin Province.
Abstract (Originalsprache)
In addressing the formidable challenge posed by methicillin-resistant Staphylococcus aureus (MRSA), this investigation elucidates a novel therapeutic paradigm by specifically targeting the virulence factor sortase A (SrtA) utilizing Tubuloside A (TnA). SrtA plays a critical role in the pathogenicity of MRSA, primarily by anchoring surface proteins to the bacterial cell wall, which is crucial for the bacterium's ability to colonize and infect host tissues. By inhibiting SrtA, TnA offers a novel and distinct strategy compared to traditional antibiotics. TnA significantly impedes Staphylococcus aureus' adherence to fibrinogen, notably disrupting biofilm development and the integration of staphylococcal protein A (SpA) into the cell wall. Enhanced survival in MRSA-infected A549 cells treated with TnA was demonstrated by live-dead cell assays, confirming its efficacy. The interaction between TnA and SrtA, as indicated by fluorescence quenching and molecular docking studies, shows that TnA has a targeted mechanism of action. Notably, TnA exhibited significant efficacy in reducing MRSA pathogenicity, as demonstrated in a murine pneumonia model. Treatment with TnA resulted in a marked decrease in the bacterial load and improved survival in infected mice. This research highlights the potential of targeting specific bacterial virulence factors as an effective strategy against antibiotic-resistant pathogens and paves the way for the development of innovative antivirulence therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Medical College, Changchun University of Chinese Medicine, Changchun, China.
- Jilin Province People's Hospital, Changchun, China.
- Surgery Center, Affiliated Hospital to Changchun University of Chinese Medicine, Changchun, China.
- Integrated Chinese and Western Medicine, Changchun University of Chinese Medicine, Changchun, China.
- Jilin Province People's Hospital, Changchun, China. lyh2388@sina.cn.
- Jilin Province People's Hospital, Changchun, China. 522677850@qq.com.
Förderung
- Education Department of Jilin Province
Zitieren
APA
Xu, Y., Luan, Y., Wang, R., Su, Z., Wang, L., Liu, Y., Jiang, G., & Wang, B. (2025). Advancing treatment strategies against MRSA: unveiling the potency of tubuloside A in targeting sortase A and mitigating pathogenicity. World Journal of Microbiology and Biotechnology. https://doi.org/10.1007/s11274-024-04185-7
Vancouver
Xu Y, Luan Y, Wang R, Su Z, Wang L, Liu Y, et al. Advancing treatment strategies against MRSA: unveiling the potency of tubuloside A in targeting sortase A and mitigating pathogenicity. World Journal of Microbiology and Biotechnology. 2025. doi:10.1007/s11274-024-04185-7
BibTeX
@article{Xu2025,
author = {Xu, Yangming and Luan, Yanhe and Wang, Rong and Su, Zhengjie and Wang, Li and Liu, Yinghui and Jiang, Guangzhi and Wang, Bingmei},
title = {Advancing treatment strategies against MRSA: unveiling the potency of tubuloside A in targeting sortase A and mitigating pathogenicity},
journal = {World Journal of Microbiology and Biotechnology},
year = {2025},
doi = {10.1007/s11274-024-04185-7}
}
EUVIMED